# Nuvation Bio Inc. (NUVB) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $6.81, market value $2.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Nuvation Bio Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 14.1×**. Each dollar of revenue is priced at 14.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 9.4×**. The shares trade at 9.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Operating margin: -81.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -325.3%**. The company reported a net loss over the last twelve months.
- **Return on equity: -66.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -55.9%**. Return on all capital, debt included, is -55.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -25.2%**. Each dollar of assets produces -25.2% of profit.

## Growth
- **Revenue growth (1 yr): 699.0%**. Revenue grew 699.0% over the last year.
- **EPS growth (1 yr): 71.6%**. Earnings per share rose 71.6%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.17**. Debt is 0.17 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.8×**. It would take 0.8 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 4.61**. A Z-score of 4.61 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Nuvation Bio Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 99.1%** (YTD -24.0%, 3-mo 41.3%). The shares are up 99.1% over twelve months including dividends.
- **From 52-week high: -30.2%** (127.8% above the low). Trading 30% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 1.75** (volatility 87%). Beta of 1.75 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NUVB · Page: https://foliofundamentals.com/stocks/nuvb

Not investment advice.